Drug Trial Radar · NCT03713619
This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
544
Actual
Start
Jan 31, 2019
Primary completion
Oct 1, 2021
Study completion Jul 26, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study also assessed the safety and tolerability of secukinumab.
Conditions
- Hidradenitis Suppurativa
Interventions
secukinumabDrug
Secukinumab 300mg every 2 or every 4 weeks
PlaceboDrug
Placebo 300mg every 2 or every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)Time frame: 16 weeks
Locations
111 sites in 29 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Rogers, Arkansas
Novartis Investigative Site
Anaheim, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Glenview, Illinois
Novartis Investigative Site
West Dundee, Illinois
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
New Brighton, Minnesota
Novartis Investigative Site
Saint Joseph, Missouri
Novartis Investigative Site
Chapel Hill, North Carolina
Novartis Investigative Site
Fairborn, Ohio
Novartis Investigative Site
Pittsburgh, Pennsylvania
Novartis Investigative Site
Charleston, South Carolina
Novartis Investigative Site
Goodlettsville, Tennessee
Novartis Investigative Site
Dallas, Texas
Novartis Investigative Site
San Antonio, Texas
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Ciudad Autonoma de Bs As, Buenos Aires, Argentina
Novartis Investigative Site
La Plata, Buenos Aires, Argentina
Novartis Investigative Site
Phillip, Australian Capital Territory, Australia
Novartis Investigative Site
Benowa, Queensland, Australia
Novartis Investigative Site
East Melbourne, Victoria, Australia
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Brussels, Brussels Capital, Belgium
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Stara Zagora, Bulgaria
Novartis Investigative Site
London, Ontario, Canada
Novartis Investigative Site
Peterborough, Ontario, Canada
Novartis Investigative Site
Waterloo, Ontario, Canada
Novartis Investigative Site
Pilsen, Czechia
Novartis Investigative Site
Prague, Prague 1, Czechia
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Créteil, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Nantes, France
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.